Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Sinopharm Group Rongsheng Pharmaceutical Co., Ltd. (Sinopharm Rongsheng for short), a wholly-owned subsidiary of the company, received the “Drug Registration Certificate” for nicardipine hydrochloride injections approved and issued by the China Drug Administration. This drug is suitable for emergency treatment of abnormal high blood pressure during surgery and emergency cases of high blood pressure. This time, Sinopharm Rongsheng's nicardipine hydrochloride injection (10ml: 10mg) obtained a drug registration certificate and was deemed to have passed the consistent evaluation, expanding the company's cardiovascular drug product range, which is conducive to further enhancing the company's comprehensive market competitiveness in related drug use fields.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.